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Abstract
Background: Transformation of chronic lymphocytic leukaemia (CLL) to diffuse large B-cell lymphoma (DLCBL) type
Richter’s syndrome (RS) carries a dismal prognosis. Standard-of-care chemoimmunotherapy for de novo RS is inadequate
with median survival of less than one year. Patients are frequently elderly or have co-morbidities limiting dose-intense
chemotherapy. Treatment of relapsed/refractory (R/R) RS and RS emerging after CLL-directed therapy represent urgent
unmet clinical needs.
Agents targeting Bruton’s tyrosine kinase (BTK) deliver improved outcomes for patients with high-risk CLL and expand
effective treatments to frailer patients. Acalabrutinib is an oral, second-generation BTK inhibitor with a favourable toxicity
profile and demonstrated activity in CLL and B-cell lymphomas. Combination of acalabrutinib with standard-of-care
CHOP-R chemoimmunotherapy offers a sound rationale to test in a prospective trial for de novo RS.
Methods: The prospective multicentre STELLAR study is designed in two elements, consisting of a randomised study to
evaluate the safety and activity of CHOP-R chemoimmunotherapy in combination with acalabrutinib in newly diagnosed
RS and single-arm studies of novel agents for other RS patient cohorts.
Eligible patients with newly diagnosed DLBCL-type RS are randomised between six cycles of CHOP-R therapy and six
cycles CHOP-R plus acalabrutinib, followed by acalabrutinib maintenance. The primary endpoint of the randomised
component is progression free survival (PFS).
Cohort 1 enrols RS patients with progressive disease following chemoimmunotherapy for acalabrutinib monotherapy.
Patients with RS diagnosed while on ibrutinib may enrol in Cohort 2, a single-arm study of CHOP-R plus acalabrutinib.
The primary endpoint for the single-arm studies is overall response rate (ORR).
Secondary endpoints for all cohorts are overall survival (OS), quality of life and proportion of patients proceeding to stem
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cell transplantation.
The study will be accompanied by exploratory analysis of the mutational landscape of RS and the relationship between
dynamic changes in sequential circulating tumour DNA samples and clinical outcomes.
Discussion: The STELLAR randomised trial evaluates the role of CHOP-R plus acalabrutinib in newly diagnosed RS
patients. The single-arm platform studies enable the incorporation of promising novel therapies into the protocol. The
STELLAR study has potential to identify novel biomarkers of treatment response in this high-risk malignancy.
Trial registration: EudraCT: 2017–004401-40, registered on the 31-Oct-2017.
IRSCTN: https://www.isrctn.com/ISRCTN52839057, registered on the 04-Mar-2019.
ClinicalTrials.gov: NCT03899337, registered on 02-April-2019.
Keywords: Richter syndrome, Richter transformation, acalabrutinib, BTK inhibitor, chronic lymphocytic leukaemia,
CHOP-R
Background
Chronic lymphocytic leukaemia (CLL) is the commonest
adult leukaemia, with an annual prevalence of 5220
cases in the UK [1, 2]. While one-third of patients do
not require treatment, the remainder progress and
follow a relapsing and remitting course. The advent of
novel oral agents targeting key components of the B-cell
receptor signalling cascade and the BCL2 receptor
antagonists have expanded treatment options for TP53
disrupted and relapsed/refractory (R/R) disease [3–7].
Similar improvements have not been observed for
patients with transformation to high-grade lymphoma or
Richter Syndrome (RS). The prognosis remains dismal
with median overall survival (OS) of 5.9–11.4 months,
representing a clear, ongoing unmet clinical need for
effective therapies [8–11].
RS complicates the disease course in 2–15% of CLL
patients [12–14]. RS is a well-recognised cause of treat-
ment failure for patients on novel agents. Progression to
RS in patients on small molecule inhibitor therapy has
been reported within two years [14]. Disease progression
and high-grade transformation is a frequent cause of
ibrutinib therapy discontinuation within a clinical trial
setting [14, 15] and in non-trial populations [16, 17].
There are currently no robust predictors of RS. TP53
disruption (deletion and/or mutation) is frequently
detected in RS [18, 19] and heralds poorer outcomes [9].
Most RS cases represent transformation to a clon-
ally related activated B-cell type (ABC) diffuse large
B-cell lymphoma (DLBCL) (90–95%), with a small
proportion transforming to Hodgkin lymphoma (HL)
[20]. Therapy for RS typically mirrors that for
DLCBL, a disease with which it shares morphological
features but the outcome is considerably worse [21].
Our group previously conducted the largest prospect-
ive multi-centre Phase II study (CHOP-OR) of RS to
date, demonstrating the feasibility of recruitment in
this uncommon haematological cancer. Incorporation
of the novel monoclonal antibody, ofatumumab in
combination with CHOP chemotherapy backbone and
as subsequent maintenance therapy did not improve
patient outcomes compared to historical results with
anthracycline-based therapy [9] with an OS of 11.4
months from diagnosis. CHOP-R (cyclophosphamide,
doxorubicin, vincristine, prednisolone and rituximab)
remains the standard front-line therapy for RS [22, 23].
Ibrutinib was the first in class oral Bruton’s tyrosine
kinase (BTK) inhibitor. It is effective in TP53-disrupted
CLL and R/R mantle cell lymphoma (MCL) [24]. Ibruti-
nib has been studied in ABC-type DLBCL where it
achieved an overall response rate (ORR) of 21–40% as
monotherapy [25, 26]. Very small cohort studies have
demonstrated some activity in RS for both ibrutinib
monotherapy (ORR 75%; 2 PR, 1 CR; n = 4) [27] and
more recently, in combination with nivolumab [28, 29]
(ORR 43–65%).
While ibrutinib is effective in CLL, the drug inhibits
off-target kinases compromising its therapeutic index
[30]. Up to 15% of ibrutinib-treated patients develop
atrial fibrillation [17]. Ventricular arrhythmias occur
an average of 788 events per 100,000 person years
[31]. The risk of ibrutinib associated hypertension ap-
pears cumulative with long-term use [32, 33]. Ibruti-
nib is associated with an increased risk of minor and
major bleeding mediated via platelet function inhib-
ition. Haemorrhagic adverse events (any grade) are re-
ported in 27–56% patients enrolled on clinical trials
[34, 35]. Concern over bleeding risk and arrhythmias
limits the use of ibrutinib in patients with comorbid
cardiovascular disease necessitating dual antiplatelet
therapy or long-term anticoagulation [34].
Acalabrutinib is a second generation oral BTK-inhibitor
which selectively and irreversibly binds cysteine residues
on BTK [36, 37].
Acalabrutinib exhibits greater selectivity in potenti-
ation of Tec and SFK mediated platelet activation com-
pared with ibrutinib [38, 39]. Pooled analysis of 610
patients treated with acalabrutinib for haematological
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malignancies reported atrial fibrillation in 2.3% and
Grade 3–5 bleeding in 2.5% following median duration
of exposure of 14.2 months [40]. No major bleeding
events were reported during the Phase 1/2 ACE-CL-
001 trial of acalabrutinib for R/R CLL [41]. Acalabruti-
nib has been approved by the FDA for treatment of R/R
MCL on the basis of a phase II trial showing ORR of
80% (ACE-LY-004) [42].
Acalabrutinib has demonstrated promise as single-
agent therapy in RS in a Phase 1b trial, including clinic-
ally meaningful responses in patients previously treated
with ibrutinib [43]. The combination of acalabrutinib
with CHOP-R is rationally designed to obtain rapid
disease control in this clinically aggressive, high-grade
B-cell lymphoma.
Methods
Trial design
The main cohort within this study is the randomised
cohort. Later in the manuscript, two further cohorts are
described. A summary of all three cohorts is highlighted
in the trial schema (Figs. 1-3).
Randomised cohort for de novo RS
The STELLAR (A phase II, randomiSed study of
CHOP-R in combination with acalabruTinib comparEd
to CHOP-R in patients with newLy diagnosed Richter’s
Syndrome and a pLAtfoRm for initial investigations into
activity of novel treatments in relapsed/refractory and
newly diagnosed Richter’s Syndrome) study is a pro-
spective, phase II randomised study of CHOP-R in
Fig. 1 Schema for randomisation and treatment for the Randomised Cohorts. CHOP-R cyclophosphamide, doxorubicin, vincristine, prednisolone
and rituximab; CR complete response; PR partial response; SD stable disease; PD progressive disease
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combination with acalabrutinib (intervention) compared
to CHOP-R alone (standard of care) for induction of re-
mission in patients with newly diagnosed RS. Patients
randomised to the interventional arm will continue on
acalabrutinib monotherapy until disease progression or
unacceptable toxicity (Fig. 1 STELLAR Trial Schema for
Participants in the Randomised trial component).
Patients randomised to standard therapy, who progress
or relapse after CHOP-R have the option to register for
Platform Cohort 1 (see below) to receive acalabrutinib
monotherapy (or an alternative novel agent if available)
until progression or unacceptable toxicity.
This multi-centre study aims to recruit 60 patients with
newly diagnosed RS (DLBCL subtype) from a minimum of
13 UK centres. Following informed consent and screening
procedures, patients are randomised 1:1 to receive either
standard of care (six cycles of CHOP-R) or the intervention.
The intervention therapy consists of six 21-day cycles of
CHOP-R (given on days 1–5) with acalabrutinib 100mg or-
ally, twice per day (B.D.) given on days 6–21. Patients on
the intervention arm will then receive acalabrutinib 100mg
B.D. as monotherapy until progression, unacceptable tox-
icity, or patient choice. Stem cell transplantation (autolo-
gous or allogenic) is a permissible consolidation strategy in
either arm in patients obtaining a durable remission at the
local investigators’ discretion.
The trial aims to recruit patients over three years, with
participants followed up for at least two years. In the event
that the treating clinician elects for stem cell transplantation
(autologous or allogenic), data on outcome will be collected.
Trial design: platform studies
The platform studies facilitate rapid incorporation of
promising novel agents into the trial. Initially, acalabruti-
nib will be evaluated in two differing RS platform cohorts.
Platform cohort 1 (progressive RS following
chemoimmunotherapy)
R/R RS following chemoimmunotherapy carries a dismal
prognosis and represents an urgent, unmet clinical need.
RS patients previously treated with anthracycline-based
chemotherapy with an anti-CD20 monoclonal antibody
(including patients progressing following randomisation
to the CHOP-R standard of care arm in STELLAR) may
register for Platform Cohort 1, where participants
receive acalabrutinib monotherapy at 100 mg B.D until
month 17, progression, unacceptable toxicity or patient
choice (Fig. 2 Trial Schema Platform Cohort 1 (Progres-
sive RS following chemo-immunotherapy)).
Platform cohort 2 (anthracycline-naïve RS patient,
diagnosed while on ibrutinib)
Anthracycline-naïve CLL patients, diagnosed with RS
while receiving ibrutinib monotherapy (defined as within
four weeks of the last dose of ibrutinib) are treated with
CHOP-R plus acalabrutinib (Fig. 3 Trial Scheme for
Platform Cohort 2 (anthracycline-naïve RS patients,
diagnosed while on ibrutinib)).
Patient selection
Eligible patients for all cohorts must be aged 16 years
and over, have an ECOG performance status of 0–3, and
have biopsy-proven DLBCL-type RS.
For the randomised cohort, patients should be newly di-
agnosed, anthracycline naïve, and lack contraindications
CHOP-R. Key inclusion criteria are outlined in Table 1.
For Platform Cohort 1, patients should have relapsed or
progressed following combination chemoimmunotherapy
with an anti-CD20 monoclonal antibody and anthracycline
containing chemotherapy. Platform Cohort 2 patients must
have been diagnosed with biopsy-proven DLBCL-type RS
within four weeks of their last dose of ibrutinib.
A histological diagnosis established by local pathology re-
view is acceptable for trial inclusion, mirroring “real-world”
clinical practice. Histological criteria for fulfilment of the
diagnosis of RS (DLBCL-subtype) include: (i) large
B-lymphoid cells with a nuclear size equal to or exceeding
that of normal macrophage nuclei or more than twice the
size of a normal lymphocyte; and (ii) diffuse growth pattern
[1, 20]. Central haematopathology review will subsequently
Fig. 2 Schema for registration and treatment of Platform Cohort 1
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be conducted at the Oxford University Hospital (OUH)
NHS Trust.
Prior treatment for CLL, including prior therapy immu-
nochemotherapy, phosphoinositide-3-kinase (PI3K) or
BCL-2 inhibitors are permissible. Ibrutinib-exposed pa-
tients who discontinue drug greater than four weeks prior
to RS diagnosis due to intolerance or adverse effects (dis-
tinct from discontinuation due to RS) are eligible for the
randomised cohort.
Patients are ineligible if they have major medical
co-morbidities, have active and uncontrolled infection
including HIV, active hepatitis B or C or other malig-
nancy requiring active treatment (with the exception of
treated non-melanoma skin cancers or cervical
intra-epithelial neoplasia). Patients with bleeding diath-
esis or requiring a vitamin K antagonist are also
excluded.
Women of childbearing potential (WOCBP) and men
whose partner is a WOCBP must use highly effective
contraception before entry, throughout the study, and
for 12 months after treatment ends.
A total of 13 Bloodwise Trials Acceleration Programme
(TAP) centres are participating in this clinical trial. (See
“Ethics approval and consent to participate” section for list
of participating centres).
Written patient information sheets (PIS) will be pre-
sented to potential trial participants alongside an over-
view of the standard of care options and the trial option.
Fig. 3 Schema for registration and treatment of Platform Cohort 2. CHOP-R cyclophosphamide, doxorubicin, vincristine, prednisolone and
rituximab; CR complete response; PR partial response; SD stable disease; PD progressive disease
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Following a period of reflection (typically a minimum of
24 h), a face-to-face consultation provides the opportun-
ity to address any queries or concerns as part of the
process of informed consent. The PIS and face-to-face
consultation will cover the nature of the study; the
known and potential adverse effects; alternative treat-
ment strategies and the study procedures and protocol.
The participant is free to withdraw from the study with-
out prejudice to future care at any time point without
the need to give a specific reason.
Interventions
All patients will be treated with six cycles of CHOP-R at
21-day intervals. This consists of rituximab 375 mg/m2
intravenously (IV), cyclophosphamide 750 mg/m2 IV,
doxorubicin 50mg/m2 IV and vincristine 1.4 mg/m2 IV
(to a maximum dose of vincristine 2 mg) on the first day
of each 21-day cycle. Oral prednisolone 40mg/m2 will
be given on day 1 to day 5 of each 21-day cycle.
The trial patients randomised to the intervention arm
will commence oral acalabrutinib 100 mg twice daily on
Day 6 and continue from day 6 to 21 of each cycle. The
acalabrutinib is interrupted during the prednisolone
therapy to facilitate the co-prescription of proton pump
inhibitors or H2 antagonist therapy.
At the conclusion of six cycles, participants rando-
mised to the intervention arm will continue on mainten-
ance oral acalabrutinib at 100 mg twice daily until
disease progression, unacceptable toxicity, patient choice
or month 17; whichever occurs first.
Pre-treatment assessment
Trial candidates with a confirmed diagnosis of RS will
undergo a pre-treatment evaluation consisting of PET-CT
scan of neck, chest, abdomen and pelvis (NCAP), a bone
marrow aspirate and trephine biopsy (BMAT), routine
haematology and biochemical testing and screening for
human immunodeficiency virus and Hepatitis B and C.
Study outcomes
Randomised trial cohort
The primary objective of the randomised study is com-
parison of progression free survival (PFS) between pa-
tients receiving the standard CHOP-R and patients
treated with CHOP-R plus acalabrutinib. PFS is defined
as the time interval from randomisation to disease pro-
gression or death with patients who are alive and pro-
gression free at the end of the study being censored at
the date last seen. Secondary objectives in the rando-
mised study are ORR after 6 cycles, quality of life (QoL),
OS, toxicity of treatment, and the proportion of patients
proceeding to haematopoietic stem cell transplantation.
Platform studies
For both Platform Cohort 1 (RS patients with progression
following chemoimmunotherapy) and Platform Cohort 2
(de novo RS diagnosed whilst taking ibrutinib), the primary
outcome is the ORR (complete response (CR) or partial re-
sponse (PR)) to acalabrutinib monotherapy after 24 weeks
of treatment (Platform Cohort 1) and CHOP-R plus acalab-
rutinib (Platform Cohort 2) after 6 cycles of treatment.
Response assessment, including PET-CT based cri-
teria, will use the categories defined by the modified
Cheson criteria [44].
Quality of life will be evaluated for participants across
all cohorts studied using the ECOG performance status
European Organisation for Research and Treatment of
Cancer (EORTC) CLL17 and NHL-HG29 questionnaires
at baseline, throughout treatment and during follow-up.
Exploratory objectives: all cohorts
The molecular mechanisms of relapse or progression of RS
following exposure to acalabrutinib have not been described.
Circulating tumour DNA (ctDNA) offers a promising
non-invasive tool to study the genomic heterogeneity of
cancer, permitting multiple samples across the disease
course, providing a dynamic evaluation of therapeutic
response to therapy and potentially allowing early detec-
tion of mutations associated with drug resistance or
transformation. Sequential evaluation of the ctDNA pro-
file during treatment has identified early responders in
HL and DLCBL [45, 46].
Mutational profiling of the RS lymphatic tissue, the
CLL lymphocytes and the circulating tumour DNA
(ctDNA), and genomic features predicting response will
be investigated. The ability of ctDNA analysis to capture
tumour heterogeneity and the relationship between dy-
namic changes in the ctDNA during treatment and other
parameters of response will be evaluated.
Exploratory objectives also include the proportion of
patients attaining minimal residual disease (MRD) nega-
tive remission (defined as CLL cells < 1 in 104 by
multi-colour flow cytometry) in each group.
Response assessment
Patients in the randomised cohorts and Platform Cohort
2 will undergo interim assessment after four cycles of
CHOP-R or 4 cycles of CHOP-R plus acalabrutinib with
a NCAP CT (after week 12). Response assessment is
performed after six cycles using PET-CT scan of NCAP
for the randomised cohorts and Platform Cohort 2. A
further PET-CT scan will be carried out at disease
progression. All Platform Cohort 1 patients receive a
CT scan at week 12 of acalabrutinib monotherapy
followed by a further PET-CT scan at week 24 and at
disease progression.
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Tissue and blood sampling
Fresh-frozen lymphatic tissue, peripheral blood (PB)
CLL cells and plasma samples ctDNA will be obtained
and subjected to whole genome and targeted deep se-
quencing. In the event of progression/relapse, a second
lymphatic tissue biopsy will be obtained. Sequential
ctDNA samples will be collected (12 per patient) during
the 24months of the trial. Serial ctDNA samples will en-
able the examination of the relationship between ctDNA
parameters and clinical and radiological response; the
link between eradication of ctDNA mutations and dur-
able remissions or clinical relapse in RS.
Statistical design
Sample size determination and power
The primary outcome for the randomised trial component
is PFS. The PFS in the CHOP-R (standard of care) is antic-
ipated to be 20% [8] with an increase to 40% in the inter-
vention arm being considered clinically significant.
A total of 54 randomised trial participants are expected
to yield a sufficient number of events at primary analysis
to compare the trial arms at one-sided significance level of
0.15 to achieve power of 80%. The sample size is based on
the log-rank test and based on the assumption of expo-
nential survival times with a recruitment over 3 years and
follow up for a minimum of 2 years. Allowing for 10%
drop-out rate, 60 participants (30 per arm) will be
recruited into the randomised component of the trial.
It is anticipated that between 21 and 30 patients will be
eligible for Platform Cohort 1 (Progressive RS following
chemoimmunotherapy). An ORR exceeding 20% will be
considered to demonstrate promising clinical activity and
the trial will use a Bayesian framework utilising a weakly-in-
formative prior of Beta [1] to establish the probability that
the true event rate exceeds this level of promising activity.
If responses are observed in 14–29% of 21 participants, the
posterior probability that the true response rate exceeds
20% is 33–87% (see Additional file 1: Table S1 Power calcu-
lations (posterior probability) for Platform Cohort 1: Pro-
gressive RS following chemo-immunotherapy).
15 participants will be recruited to Platform Cohort 2
(anthracycline-naïve RS patients, diagnosed while on ibru-
tinib). For this group, CHOP-R with acalabrutinib will be
considered to demonstrate promising clinical activity if the
ORR exceeds 50%. As with cohort 1 a Bayesian approach
utilising a Beta [1] prior. If responses are observed in 8–11
patients, the posterior probability that the true response
rate is greater than 50% is 60–96% (see Additional file 2:
Table S2 Power calculations for Platform Cohort 2:
(anthracycline-naïve RS, diagnosed while on ibrutinib)).
Statistical analysis plan
The randomised component of the trial will be analysed
independently of each of the platform cohorts. The
primary outcome analysis will be performed on an
intention to treat basis for all cohorts. Additional ana-
lysis will be carried out on a safety population including
patients who have received at least one dose of trial
treatment. All analysis will take place once all partici-
pants have completed 2 years of follow up.
The primary analysis of the randomised cohort will be
carried out using the cox proportional hazards model.
Hazard ratios, with corresponding confidence intervals
will be presented for comparison of the two treatments
under the assumption of proportional hazards.
The primary analysis of cohort 1 and 2 will be Bayesian in
nature. For each cohort, posterior probability plots of the re-
sponse rate at the time-point of interest will be produced
and the number and proportion of responders will be pre-
sented. In addition, the probability that the true response
rate is greater than clinically relevant values will be provided.
OS, PFS and duration of response for all groups will
be presented using Kaplan-Meier plots with estimates
and corresponding confidence intervals presented at 6
months, 1 year and 2 years. Log rank tests will be used
to compare between treatment arms for the randomised
component of the trial. Categorical values will be
tabulated and compared between treatment arms using
chi-squared tests or Fishers exact test as appropriate for
the randomised component of the trials.
Patient reported outcomes will be presented using
descriptive statistics.
The safety population (all participants who received at
least one dose of trial treatment) will be used to evaluate
safety outcomes. The number of adverse events (AE)
and the number of patients experiencing AEs will be
summarised by system class for serious AE (SAE) and
presented by AE with Common Terminology Criteria
for Adverse Events (CTCAE) grade ≥ 1, AE with CTCAE
≥3 and AE related to acalabrutinib.
We will perform exploratory analysis on this well-de-
fined RS patient dataset. The relationship between the
genomic features (including specific gene mutations,
genomic complexity) and clinical outcomes will be
assessed. Gene mutational analysis will be performed on
tissue and sequential plasma ctDNA samples for all par-
ticipants but will not influence treatment.
Planned subgroup analysis
Subgroup analysis will be carried out for the randomised
trial component to assess the effect of the treatment
with regards to the primary outcome and TP53 status
(disrupted or intact).
Monitoring committee
The independent DMC will review the unblinded trial
data on an annual basis in order to monitor safety,
recruitment, data quality and activity.
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Safety, discontinuation of treatment and
premature termination of the trial
SAEs and AEs will be evaluated for grade, duration, type,
onset, and relationship to study investigational medicinal
product (IMP) according to the National Cancer Institute
CTCAE V4.03 (https://www.eortc.be/services/doc/ctc/
CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf). AEs
related to acalabrutinib will be assessed against the Inves-
tigator Brochure (IB) and AE related to other drugs (non--
IMP) will be appraised against the appropriate Summary
of Product Characteristics (SmPC). Trial site staff carry re-
sponsibility for detection, documentation and reporting of
suspected AE or SAE to the STELLAR Trial Office.
If at interim assessment or end of treatment assessment,
the disease response is stable disease (SD) or progressive
disease (PD), the patient should receive no further treat-
ment on study with the exception of participants rando-
mised to CHOP-R, who may enrol in Platform Cohort 1
at progression. Patients may be withdrawn from the trial if
the investigator judges it to be in necessary for their med-
ical care, the patient becomes pregnant or the patient
wishes to discontinue. Patients may withdraw consent
from participation at any point during the trial and no
further trial samples will be taken.
The Trial Sponsor, the STELLAR Trial Office and the
Chief Investigator (CI) reserve the right to suspend or
terminate the study for reasons including (but not lim-
ited to) safety concerns or ethical issues.
Trial Organisational structure
The trial is being conducted under the auspices of the
Cancer Research UK Clinical Trials Unit (CRCTU) and
sponsored by University of Birmingham.
A Trial Management Group (TMG) will be established
to include the Chief Investigator (CI), co-investigators,
the trial statistician and trial coordinators. Notwith-
standing the legal obligations of the Sponsor and CI, the
TMG will be responsible for the daily running and man-
agement of the trial. The STELLAR trial is run in ac-
cordance with the principles of the Declaration of
Helsinki, the UK Clinical Trials Regulations and the
policies of the participating NHS trusts. A Trial Safety
Committee (TSC), with an independent chair, will
provide overall supervision for the STELLAR trial and
retain ultimate responsibility for the continuation of
the trial.
Confidential data analysis will be supplied to an inde-
pendent Data Monitoring Committee (DMC), operating
in line with a trial specific charter. The DMC will meet
one month prior to the due date of the Development
Safety Update Report (DSUR) during the recruitment
phase and at least annually thereafter. An emergency
meeting may be called if a safety issue is identified.
Confidentiality
Confidential information collected during the trial will
be stored in accordance with the General Data Protec-
tion Regulation (GDPR) 2018. As specified in the PIS
and with the patients consent, patients will be identified
using only their date of birth and unique trial ID num-
ber. Authorised staff may have access to the records for
quality assurance and audit purposes. The Trials Office
maintains the confidentiality of all patients’ data and will
not disclose information by which patients may be iden-
tified to any third party other than those directly in-
volved in the treatment of the patient and organisations
for which the patient has given explicit consent for data
transfer (e.g. laboratory staff ).
Dissemination of results and publication policy
The Trial Sponsor and investigators recognise their
responsibility to appropriately disseminate and publish
results under the Research Governance Framework for
Health and Social Care. The clinical trial results will be
submitted for publication in a peer reviewed scientific
journal publication, with authorship determined in
accordance with TAP publication policy.
Discussion
The STELLAR trial evaluates the safety, feasibility and
clinical activity of the addition of acalabrutinib to stand-
ard CHOP-R and subsequent acalabrutinib maintenance
compared with CHOP-R for RS. It represents an ambi-
tious and historical study; being the first randomised
clinical trial ever to be performed in RS. The activity of
acalabrutinib monotherapy in CLL and other B-cell
lymphomas, together with its favourable safety profile of
acalabrutinib with CHOP-R provides a clear therapeutic
rationale for the STELLAR trial. The gap between the
closure of the CHOP-OR study, the last interventional
trial in RS and opening STELLAR will be over three
years. This means that during this timeframe, patients
with this rare and devastating disease did not have ac-
cess to a clinical trial. Thanks to single-arm platform
studies within STELLAR, new agents and combinations
can now be evaluated without the need for closing and
opening new studies.
For example, a recent Phase II trial of nivolumab com-
bined with ibrutinib reported a 43% ORR in a cohort of
RS patients with prior exposure targeted therapies [29].
However, duration of response in the responding pa-
tients was only 9.3 months, hardly better than previous
studies of CHOP-R [8]. PI3K-inhibition in combination
with PD-1 inhibition and an anti-CD20 might be a more
attractive option: The Phase I/II study of umbralisib
(TGR-1202) in combination with ublituximab (TG-1101)
and pembrolizumab in patients with R/R CLL or RS has
so far evaluated 4/5 RS patients showed a 50% ORR (2/
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4, CR). The two patients achieving CR experience
durable disease control at 7 and 15months follow-up
respectively. Both patients were ibrutinib refractory and
had 7 (including stem cell transplant) and 8 prior lines
of therapy, and one had failed CAR-T [47].
In addition to addressing important clinical questions,
the STELLAR trial is accompanied by extensive biobank-
ing and also aims to further develop our understanding of
the genomic landscape of RS and to generate insights into
dynamic changes in the ctDNA profile during treatment.
In conclusion, our experience with CHOP-OR has
shown that there is considerable interest both in the UK
and in Europe in recruiting patients into a study exclu-
sively dedicated to patients with RS.
We are excited that STELLAR will be first to offer
novel therapies to patients with newly diagnosed and
also with relapsed RS, and we will consider extending
the study to other European centres.
Additional files
Additional file 1: Table S1. Power calculations (posterior probability)
for Platform Cohort 1: Progressive RS following chemo-immunotherapy.
(DOCX 15 kb)
Additional file 2: Table S2. Power calculations for Platform Cohort 2:
(anthracycline-naïve RS, diagnosed while on ibrutinib). (DOCX 15 kb)
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